Stocks under Analysts’ radar: Synacor Inc (NASDAQ:SYNC), Immune Pharmaceuticals Inc (NASDAQ:IMNP)

0
124

Synacor Inc (NASDAQ:SYNC) Stats:

The stock gained 9.22% and closed its last session at $3.08. The Company has the market capitalization of 88.10 Million. The 52-Week Range ranges between $1.03 and $3.98. The stock traded with the Volume of 1.72 Million in the last trading day whereas, the Average Volume of the stock is at 1.75 Million. The Total Outstanding Shares of the company are 30.02 Million.

The company reported the sales of 113.80 Million (TTM) while the income reported by the stock is at -4.00 Million. The Price to Sales P/S stands at 0.83 and Price to Book P/B value is at 6.01 for the stock.

The distance from 20 days simple moving Average (SMA20) is 20.03 Percent while SMA50 shows the value of 60.95%. The company will report its next Earnings on Aug 2 – Aug 8 (Est.). The 1 year Target estimate for the company is 4.50.

While looking at the Growth Estimate, the Stock has the current quarter estimated growth of -150.00% and for the next fiscal quarter estimated growth is -333.30%. The company is currently projecting its Next 5 years (per annum) growth of 25.00%.

Immune Pharmaceuticals Inc (NASDAQ:IMNP) Stats:

The stock closed its last session with the fall of -9.04% and reached at $0.236. The stock traded with the Volume of 1.08 Million whereas its Average Volume is at 304,934.00 Shares. The Current Market Capitalization of the company is at 9.26 Million. The 52 week Low range is $0.21 while its 52-week High Range is $2.23. The total outstanding shares of the company appeared as 40.95 Million.

The company reported the income (ttm) of -24.10 Million. The P/B are 2.96 respectively.

The distance from 20 days simple moving Average (SMA20) is -30.24 Percent while SMA50 shows the value of -41.75%. The company will report its next Earnings on Aug 15 – Aug 19 (Est.). The 1 year Target estimate for the company is 2.00.

The stock has current Fiscal Quarter Growth estimate and the Upcoming (Next) Fiscal quarter Growth Estimate of -8.30% and 63.60% respectively.

 Analysts Opinions/Ratings

The Analyst Stock Recommendations are determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, Underperform or Sell.

According to Zacks Investment Research, 0 analyst has rated the stock with a sell rating, 0 have assigned a hold rating, 0 says it’s a buy, and 4 have assigned a strong buy rating to the company.